Results 141 to 150 of about 256,425 (387)

Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) [PDF]

, 2008
<p><b>Background and Purpose:</b> The Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) unadjusted results demonstrated that intravenous alteplase is well tolerated and that the effects were comparable with ...
Ahmed, Niaz, Aichner, Franz, Bluhmki, Erich, Davalos, Antoni, Eriksson, Niclas, Erilä, Terttu, Ford, Gary A, Grond, Martin, Hacke, Werner, Hennerici, Michael G, Kaste, Markku, Köhrmann, Martin, Larrue, Vincent, Lees, Kennedy R, Machnig, Thomas, Peeters, André, Roine, Risto O, Toni, Danilo, Vanhooren, Geert, Wahlgren, Nils   +19 more
core   +2 more sources

Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy [PDF]

, 2013
Thomas Gremmel, Markus Müller, Sabine Steiner, Daniela Seidinger, Renate Koppensteiner, Christoph Kopp, Simon Panzer   +6 more
openalex   +1 more source

Prolonged Dual Antiplatelet Therapy in Acute Myocardial Infarction Patients without Revascularization: Results from a China Acute Myocardial Infarction (CAMI) registry study [PDF]

, 2023
Cunrong Huang, Jingang Yang, Ling Li, Shenghu He, Xuxia Zhang, Haiyan Xu, Yuan Wu, Jun Zhang, Shubin Qiao, Yongjian Wu, Yanyan Zhao, Yang Wang, Wei Li, Chen Jin, Xiaojin Gao, Yuejin Yang   +15 more
openalex   +1 more source

Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta‐Analysis, and New Insights From the CLOSE Study

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2018
Background We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) comparing patent foramen ovale (PFO) closure, anticoagulation, and antiplatelet therapy to prevent stroke recurrence in patients with PFO‐associated ...
G. Turc, D. Calvet, P. Guérin, M. Sroussi, G. Chatellier, J. Mas   +5 more
semanticscholar   +1 more source

Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database

Clinical Pharmacology &Therapeutics, EarlyView.
Disproportionality analyses suggested a cardiovascular risk signal for romosozumab, while statistically significant associations were not found in the real‐world database studies. Therefore, a larger comparative study was necessary to examine this signal.
Hotaka Maruyama, Eiko Iwasa, Shinya Watanabe, Tomoaki Hasegawa, Kazuhiro Kajiyama, Taihei Tanaka   +5 more
wiley   +1 more source

Dipyridamole plus aspirin versus aspirin alone in the secondary prevention after TIA or stroke: a meta-analysis by risk [PDF]

, 2008
Objectives: Our aim was to study the effect of combination therapy with aspirin and dipyridamole (A+D) over aspirin alone (ASA) in secondary prevention after transient ischemic attack or minor stroke of presumed arterial origin and to perform subgroup ...
A Algra, B Guiraud-Chaumeil, F M Yatsu, H-C Diener, L J Gray, P H A Halkes, P M W Bath   +6 more
core   +2 more sources

Duration of Dual Antiplatelet Therapy and Long-Term Clinical Outcome After Coronary Drug-Eluting Stent Implantation [PDF]

, 2012
Tomohisa Tada, Masahiro Natsuaki, Takeshi Morimoto, Yutaka Furukawa, Yoshihisa Nakagawa, Robert A. Byrne, Adnan Kastrati, Kazushige Kadota, Masashi Iwabuchi, Satoshi Shizuta, Junichi Tazaki, Hiroki Shiomi, Mitsuru Abe, Natsuhiko Ehara, Tetsu Mizoguchi, Hirokazu Mitsuoka, Tsukasa Inada, Makoto Araki, Satoshi Kaburagi, Ryoji Taniguchi, Hiroshi Eizawa, Akira Nakano, Satoru Suwa, Akinori Takizawa, Ryuji Nohara, Hisayoshi Fujiwara, Kazuaki Mitsudo, Masakiyo Nobuyoshi, Toru Kita, Takeshi Kimura   +29 more
openalex   +1 more source

Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease: Focus on the COMPASS Trial

Circulation, 2019
Antiplatelet therapy is the mainstay for the treatment of acute and chronic arterial disease involving the coronary and peripheral beds. However, questions remain about optimal antithrombotic therapy for long-term treatment of chronic vascular disease ...
P. Gurbel, K. Fox, U. Tantry, H. ten Cate, J. Weitz   +4 more
semanticscholar   +1 more source

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation

Clinical Pharmacology &Therapeutics, EarlyView.
From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park, Jae‐Hwan Lee, Jin‐Ok Jeong, Diana A. Gorog, Udaya S. Tantry, Byeong‐Keuk Kim, Hyung Joon Joo, Kiyuk Chang, Jin‐Yong Hwang, Young Bin Song, Sung Gyun Ahn, Jung‐Won Suh, Woong Gil Choi, Jung Rae Cho, Jeehoon Kang, Sang Yeub Lee, Hyo‐Soo Kim, Moo Hyun Kim, Do‐Sun Lim, Eun‐Seok Shin, Paul A. Gurbel, Young‐Hoon Jeong, on behalf of the PTRG‐DES Consortium Investigators   +22 more
wiley   +1 more source

Ticagrelor versus clopidogrel in the management of acute myocardial infarction

Journal of Community Hospital Internal Medicine Perspectives, 2019
Hypothesis: In the care of acute myocardial infarction, ticagrelor attenuates post-ischemic myocardial damage and inhibits platelet activity to a greater extent than clopidogrel.
Candice Volney, Anthony Collins, Sarah Adams   +2 more
doaj   +1 more source